natgillin/translations-raw huggingface dataset:
Almindelig eller usødet chokolade- sirup, honning (kun for børn, der er 2 år eller ældre), lysebrun farin eller bordsukker opløst i vand, dessert, sødet kondenseret mælk, æblemos eller yoghurt.
15 During situations when commercially manufactured Tamiflu oral suspension is not readily available, adults, adolescents or children who are unable to swallow capsules may receive appropriate doses of Tamiflu (see section 3 in Package Leaflet) by opening capsules and pouring the contents of capsules into a suitable, small amount (1 teaspoon maximum) of sweetened food product such as regular or sugar-free chocolate syrup, honey (only for children two years or older), light brown or table sugar dissolved in water, dessert toppings, sweetened condensed milk, apple sauce or yogurt to mask the bitter taste.
Følgende vægtjusterede doser anbefales:
The following weight-adjusted dosing regimens are recommended:
16 Særlige populationer Leverinsufficiens Justering af dosis er ikke nødvendig hos patienter med leverinsufficiens, hverken til behandling eller forebyggelse.
16 Special populations Hepatic impairment No dose adjustment is required either for treatment or for prevention in patients with hepatic dysfunction.
Creatininclearance > 30 (ml/ min) > 10 til ≤30 (ml/ min)
Creatinine clearance > 30 (ml/ min) > 10 to ≤ 30 (ml/ min)
eller 30 mg suspension to gange daglig eller 30 mg kaplser to gange daglig
Recommended dose for treatment 75 mg twice daily 75 mg once daily, or 30 mg suspension twice daily, or 30 mg capsules twice daily
eller 30 mg suspension en gang daglig eller 30 mg kapsel en gang daglig
Recommended dose for prevention 75 mg once daily 75 mg every second day, or 30 mg suspension once daily, or 30 mg capsules once daily
Effekten af oseltamivir til behandling af patienter med kroniske hjertesygdomme og/ eller åndedrætssygdomme er ikke dokumenteret.
17 Efficacy of oseltamivir in the treatment of subjects with chronic cardiac disease and/ or respiratory disease has not been established.
17 Tamiflu er ikke en erstatning for influenzavaccination.
Tamiflu is not a substitute for influenza vaccination.
Hos voksne var de hyppigste bivirkninger opkastning og kvalme i behandlingsstudierne og kvalme og hovedpine i forebyggelsesstudierne.
In adults, the most commonly reported adverse drug reactions (ADRs) were vomiting and nausea in the treatment studies, and nausea and headache in the prevention studies.
Den hyppigste bivirkning hos børn var opkastning.
The majority of these ADRs
18 Bivirkningerne som fremgår af nedenstående tabel, opdeles i følgende kategorier:
18 were reported on a single occasion on either the first or second treatment day and resolved spontaneously within 1-2 days.
19 Systemorganklasse Frekvensgruppe
19 System Organ Class (SOC) Frequency Category
De hyppigste bivirkninger (≥ 1% i oseltamivir- gruppen i behandlingsstudierne og ≥ 10% i oseltamivir- guppen i forebyggelsesstudiet) i børn.
Most Frequent Adverse Drug Reactions (≥ 1% in the oseltamivir group in the treatment studies and ≥ 10 in the oseltamivir group in the prophylaxis study) in Children
Oseltamivir 30 - 75 mgb
30 to 75 mgb
Oseltamivir 30 - 75 mgb
30
158)
(n = 158)
Lungebetændelse Sinuitis Bronkitis Otitis media Blod og lymfesystem Almindelig:
Sinusitis Bronchitis Otitis media
Lymfeknudesvulst
Lymphadenopathy
Astma (inkl. forværret) Næseblod
Asthma (incl. aggravated) Epistaxis
4% 4% 3% 3%
4% 4% 3% 3%
Mave- tarmkanalen Meget almindelig:
Gastrointestinal disorder Very Common:
0%
3%
20 Systemorganklasse Frekvensgruppe
20 System Organ Class (SOC) Frequency Category
(n = 515)
(n = 515)
(n = 517)
= 517)
Overfølsomhedsreaktioner, inklusive anafylaktiske/ anafylaktoide reaktioner.
Immune system disorders Frequency not known: hypersensitivity reactions, including anaphylactic/ anaphylactoid reactions.
Alvorlige hudreaktioner, inklusive Steven- Johnsons syndrom, toksisk epidermal nekrolyse, erythema multiforme og angioneurotisk ødem.
21 Skin and subcutaneous tissue disorders Frequency not known: severe skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme and angioneurotic oedema.
21 Yderligere information omkring specifikke populationer:
Additional information on special populations:
Patienter med resistensmutationer%
22 Patients with Resistance Mutations (%)
22 Andelen af resistensudvikling kan være højere i de yngste aldersgrupper og hos immunsupprimerede patienter.
The rate of emergence of resistance may be higher in the youngest age groups, and in immunosupressed patients.
Oseltamivir- resistente vira, isoleret fra oseltamivirbehandlede patienter og oseltamivir - resistente laboratoriestammer af influenzavira har mutationer i N1 - og N2- neuraminidaser.
Oseltamivir-resistant viruses isolated from oseltamivir-treated patients and oseltamivir-resistant laboratory strains of influenza viruses have been found to contain mutations in N1 and N2 neuraminidases.
Oseltamivir nedsatte incidensen af akut otitis media fra 26, 5% (53/ 200) i placebogruppen til 16% (29/ 183) i oseltamivirgruppen (p = 0, 0013).
23 reduced the incidence of acute otitis media from 26.5% (53/ 200) in the placebo group to 16% (29/ 183) in the oseltamivir treated children (p = 0.013).
Efter
In the oseltamivir treated group, the median duration of illness was not reduced significantly.
23 6 dage (sidste behandlingsdag) øgedes FEV1 med 10, 8% i oseltamivirgruppen sammenlignet med 4, 7% i placebogruppen (p=0, 0148).
By day 6 (the last day of treatment) FEV1 had increased by 10.8% in the oseltamivir treated group compared to 4.7% on placebo (p = 0.0148) in this population.
Behandling af influenza B:
Treatment of influenza B infection:
24- 50).
The NNT in this study was 28 (95% CI 24 – 50).
24 I et studie hos ældre beboere i plejehjem, hvoraf 80% blev vaccineret i studieperioden, nedsatte 6 ugers behandling med oseltamivir, 75 mg en gang daglig, signifikant hyppigheden af klinisk influenza fra 12/ 272 (4, 4%) i placebogruppen til 1/ 276 (0, 4%) i oseltamivirgruppen (92% reduktion [95% konfidensinterval 1, 5 - 6, 6, p=0, 0015]).
A study in elderly residents of nursing homes, where 80% of participants received vaccine in the season of the study, oseltamivir 75 mg once daily given for 6 weeks significantly reduced the incidence of clinical influenza illness from 12/ 272 (4.4%) in the placebo group to 1/ 276 (0.4%) in the oseltamivir group (92% reduction [95% CI 1.5 – 6.6; p = 0.0015]).
In- vitro- studier har vist at hverken oseltamivir eller den aktive metabolit er substrat for eller hæmmer af cytokrom P450 - isoenzymer.
In vitro studies demonstrated that neither oseltamivir nor the active metabolite is a substrate for, or an inhibitor of, the major cytochrome P450 isoforms.
Elimination Absorpberet oseltamivir elimineres primært (> 90%) ved omdannelse til oseltamivircarboxylat.
Elimination Absorbed oseltamivir is primarily (> 90%) eliminated by conversion to oseltamivir carboxylate.
25 Børn Oseltamivirs farmakokinetik er undersøgt i et enkeltdosis farmakokinetisk studie med børn i alderen 1 til 16 år.
25 Children The pharmacokinetics of oseltamivir have been evaluated in single-dose pharmacokinetic studies in children aged 1 to 16 years.
Yngre børn udskilte både prodrug’ en og dens aktive metabolit hurtigere end voksne, resulterende i en lavere eksponering for en given mg/ kg- dosis.
Younger children cleared both the pro-drug and its active metabolite faster than adults, resulting in a lower exposure for a given mg/ kg dose.
Doser på 2 mg/ kg giver oseltamivircarboxylat- eksponeringer som er sammenlignelige med dem, der opnås hos voksne, som får en enkelt dosis på 75 mg (ca.
Doses of 2 mg/ kg give oseltamivir carboxylate exposures comparable to those achieved in adults receiving a single 75 mg dose (approximately 1 mg/ kg).
Oseltamivirs farmakokinetik hos børn over 12 år svarer til voksnes.
The pharmacokinetics of oseltamivir in children over 12 years of age are similar to those in adults.
Resultater fra de konventionelle carcinogene studier på gnavere viste en tendens mod en dosisafhængig øgning i udbredelsen af nogle tumorer, som er typiske for den gnaverrace, der blev anvendt.
Results of the conventional rodent carcinogenicity studies showed a trend towards a dose-dependent increase in the incidence of some tumours that are typical for the rodent strains used.
Gelatine Sort jernoxid (E172) Titandioxid (E171)
Gelatin Black iron oxide (E172) Titanium dioxide (E171)
26 Det påtrykte blæk:
26 Printing ink:
EU/ 1/ 02/ 222/ 004 9.
EU/ 1/ 02/ 222/ 004
Tamiflu 75 mg hårde kapsler.
Tamiflu 75 mg hard capsule.
Hårde kapsler De hårde kapsler består af en grå, ugennemsigtig krop, påtrykt ” ROCHE ” og en lysegul, ugennemsigtig hætte, påtrykt ” 75 mg ”.
Hard capsule The hard capsule consists of a grey opaque body bearing the imprint “ ROCHE” and a light yellow opaque cap bearing the imprint “ 75 mg”.
Almindelig eller usødet chokolade- sirup, honning (kun for børn, der er 2 år eller ældre), lysebrun farin eller bordsukker opløst i vand, dessert, sødet kondenseret mælk, æblemos eller yoghurt.
28 During situations when commercially manufactured Tamiflu oral suspension is not readily available, adults, adolescents or children who are unable to swallow capsules may receive appropriate doses of Tamiflu (see section 3 in Package Leaflet) by opening capsules and pouring the contents of capsules into a suitable, small amount (1 teaspoon maximum) of sweetened food product such as regular or sugar-free chocolate syrup, honey (only for children two years or older), light brown or table sugar dissolved in water, dessert toppings, sweetened condensed milk, apple sauce or yogurt to mask the bitter taste.
Dette vil maskere den bitre smag.
The mixture should be stirred and the entire contents given to the patient.
Blandingen bør omrøres og gives til patienten.
The mixture must be swallowed immediately after its preparation.
Hele blandingen bør sluges straks efter opblanding.
It is not necessary to administer any undissolved white powder as this is inert material.
Se produktresumeet for Tamiflu- suspension og Tamiflu 30 mg og 45 mg kapsler vedrørende den anbefalede dosis af Tamiflu til spædbørn, som er 1 år eller ældre og til børn i alderen 2 til 12 år.
For recommended treatment dose of Tamiflu for infants older than 1 year of age and for children 2 to 12 years of age, see SmPC of Tamiflu suspension and Tamiflu 30 and 45 mg capsules.
Børn, som vejer mere end 40 kg, og som kan sluge kapsler, kan behandles med en voksendosis på 75 mg to gange daglig i 5 dage som et alternativ til den anbefalede dosis af Tamiflu- suspension eller Tamiflu 30 mg eller 45 mg kapsler.
Children weighing > 40 kg and who are able to swallow capsules may receive treatment with the adult dosage of 75 mg capsules twice daily for 5 days as an alternative to the recommended dose of Tamiflu suspension or Tamiflu 30 mg and 45 mg capsules.
Forebyggelse af influenza Forebyggelse efter udsættelse for smitte Til unge (13 – 17 år) og voksne:
Prevention of influenza Post-exposure prevention For adolescents (13 to 17 years of age) and adults:
Se produktresumeet for Tamiflu- suspension og Tamiflu 30 mg og 45 mg kapsler vedrørende den anbefalede profylaktiske dosis af Tamiflu til spædbørn, som er 1 år eller ældre og til børn i alderen 2 til 12 år, som har været udsat for smitte.
For recommended post-exposure prevention dose of Tamiflu for infants older than 1 year of age and for children of 2 to 12 years of age, see SmPC of Tamiflu suspension and Tamiflu 30 mg and 45 mg capsules.
Børn, der vejer > 40 kg og som kan sluge kapsler, kan som forebyggende behandling også tage 75 mg kapsler én gang daglig i 10 dage som et alternativ til den anbefalede dosis af Tamiflu- suspension eller Tamiflu 30 mg og 45 mg kapsler.
Children weighing > 40 kg and who are able to swallow capsules may receive prevention with a 75 mg capsule once daily for 10 days as an alternative to the recommended dose of Tamiflu suspension or Tamiflu 30 mg and 45 mg capsules.
Særlige populationer Leverinsufficiens Justering af dosis er ikke nødvendig hos patienter med leverinsufficiens, hverken til behandling eller forebyggelse.
Special populations Hepatic impairment No dose adjustment is required either for treatment or for prevention in patients with hepatic dysfunction.
Justering af dosis anbefales til voksne patienter med svær nyreinsufficiens.
No studies have been carried out in paediatric patients with hepatic disorder.
29
29 Renal impairment Treatment of influenza:
Creatininclearance > 30 (ml/ min)
Dose adjustment is recommended for adults with severe renal impairment.
Anbefalet dosis til behandling 75 mg to gange daglig
Recommended doses are detailed in the table below.
> 10 til ≤ 30 (ml/ min)
Creatinine clearance > 30 (ml/ min) > 10 to ≤ 30 (ml/ min)
Effekten af oseltamivir til behandling af patienter med kroniske hjertesygdomme og/ eller åndedrætssygdomme er ikke dokumenteret.
Efficacy of oseltamivir in the treatment of subjects with chronic cardiac disease and/ or respiratory disease has not been established.
Beskyttelsen imod influenza varer kun så længe som der gives Tamiflu.
The protection against influenza lasts only as long as
30 Svær nyreinsufficiens Dosisjustering er nødvendig både ved behandling og forebyggelse hos patienter med svær nyreinsufficiens.
Tamiflu should be used for the treatment and prevention of influenza only when reliable epidemiological data indicate that influenza virus is circulating in the community.
Den samlede sikkerhedsprofil for Tamiflu er baseret på data fra kliniske studier omfattende 2107 voksne og 1032 børn behandlet for influenza, og på data fra kliniske studier med over 2914 voksne og 99 børn, som fik Tamiflu til forebyggelse af influenza.
The overall safety profile of Tamiflu is based on data from 2107 adult and 1032 paediatric patients treated for influenza, and on data from 2914 adult and 99 paediatric patients receiving Tamiflu for the prophylaxis of influenza in clinical trials.
De fleste af disse bivirkninger blev kun rapporteret en enkelt gang, enten på første eller anden behandlingsdag, og forsvandt spontant i løbet af 1- 2 dage.
The majority of these ADRs were reported on a single occasion on either the first or second treatment day and resolved spontaneously within 1-2 days.
Bivirkningerne som fremgår af nedenstående tabel, opdeles i følgende kategorier:
The ADRs listed in the tables below fall into the following categories:
Meget almindelig (≥ 1/ 10), almindelig (≥ 1/ 100 til < 1/ 10), ikke almindelig (≥ 1/ 1. 000 til < 1/ 100), sjælden (≥ 1/ 10. 000 til < 1/ 1. 000) og meget sjælden (< 1/ 10. 000) og ukendt (kan ikke vurderes ud fra foreliggende data).
Very Common (≥ 1/ 10), Common (≥ 1/ 100 to < 1/ 10), Uncommon (≥ 1/ 1,000 to < 1/ 100), Rare (≥ 1/ 10,000 to < 1/ 1,000), Very
31 Behandling og forebyggelse af influenza hos voksne og unge:
Treatment and prevention of influenza in adults and adolescents:
8%
3% 2% 8% 1%
4%
1% 2% 3% 2%
Opkastningc Mavesmerter Diarré Dyspepsi Hud og subkutane væv Ikke almindelig:
Skin and subcutaneous tissue disorders Uncommon:
8% 2% 6% 1%
1% < 1% 1%
3% 2% 8% 1%
1%
2% 2% 3% 2%
< 1% < 1% < 1% < 1% 0% < 1%
1% 2% 3% 2%
< 1% < 1% < 1%
Dermatitisb Udslætb Nældefeberb Eksemb Almene symptomer Almindelig:
General disorders Common:
< 1% < 1% < 1% < 1%
(n = 1057)
< 1% < 1% < 1% 0%
(n = 1050)
1% < 1% < 1% < 1%
(n = 1480)
1% < 1% < 1% < 1%
(n = 1434)
Svimmelhed Træthed Smerte
Dizziness Fatigue Pain
32 c Forskellen mellem placebo og oseltamivir grupperne var statistisk signifikant.
They were also reported in the pooled clinical studies at the incidence presented in the table above. b Subjects who experienced nausea alone; excludes subjects who experienced nausea in association with vomiting. c The difference between the placebo and oseltamivir groups was statistically significant.
(n = 517)
517)
= 158)
(n = 158) (n =
99)
99)
Lymfeknudesvulst Luftveje, thorax og mediastinum Almindelig:
Disorders of the blood and lymphatic system Common:
Astma (inkl. forværret) Næseblod Mave- tarmkanalen Meget almindelig:
Respiratory, thoracic and mediastinal disorders Common:
1% 1%
10%
Opkastning Diarré Almindelig:
Diarrhoea
15% 10%
10%
9% 11%
11%
20% 3%
3%
Kvalme Mavesmerter Øjne Almindelig:
Nausea Abdominal pain
Conjunctivitis Øre og labyrint Almindelig:
Conjunctivitis
Ørelidelserc Trommehindelidelser Hud og subkutane væv Almindelig:
Disorders of the ear and labyrinth Common:
2% 1%
(n = 517)
33 Yderligere data fra post- marketing overvågning omkring udvalgte alvorlige bivirkninger:
Further post marketing surveillance data on selected serious adverse drug reactions:
Alvorlige hudreaktioner, inklusive Steven- Johnsons syndrom, toksisk epidermal nekrolyse, erythema multiforme og angioneurotisk ødem.
Skin and subcutaneous tissue disorders Frequency not known: severe skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme and angioneurotic oedema.
Yderligere information omkring specifikke populationer:
34 Additional information on special populations:
Patienter med resistensmutationer%
Patients with Resistance Mutations (%)
Andelen af resistensudvikling kan være højere i de yngste aldersgrupper og hos immunsupprimerede patienter.
The rate of emergence of resistance may be higher in the youngest age groups, and in immunosupressed patients.
Oseltamivir- resistente vira, isoleret fra oseltamivirbehandlede patienter og oseltamivir - resistente laboratoriestammer af influenzavira har mutationer i N1 - og N2- neuraminidaser.
35 oseltamivir-resistant laboratory strains of influenza viruses have been found to contain mutations in N1 and N2 neuraminidases.
Af de ældre patienter var 64% influenza- positive og af de der havde kronisk hjerte - og/ eller luftvejslidelse var
Of the elderly subjects, 64% were influenza-positive and of those with chronic cardiac and/ or respiratory disease 62% were influenza-positive.
Behandling med oseltamivir påbegyndt senest 48 timer efter symptomstart, nedsatte tiden indtil helbredelse af sygdommen signifikant (defineret som samtidig mildning af hoste, forstoppet næse, feber og forældrenes rapportering om barnets tilbagevenden til normalt helbred og normal aktivitet) med 1, 5 dag (95% konfidensinterval:
Oseltamivir treatment, started within 48 hours of onset of symptoms, significantly reduced the time to freedom from illness (defined as the simultaneous return to normal health and activity and alleviation of fever, cough and coryza) by 1.5 days (95% CI 0.6 – 2.2 days; p < 0.0001) compared to placebo.
Oseltamivir nedsatte incidensen af akut otitis media fra 26, 5% (53/ 200) i placebogruppen til 16% (29/ 183) i oseltamivirgruppen (p = 0, 0013).
Oseltamivir reduced the incidence of acute otitis media from 26.5% (53/ 200) in the placebo group to 16% (29/ 183) in the oseltamivir treated children (p = 0.013).
Behandling af influenza B:
36 Treatment of influenza B infection:
36 Forebyggelse efter smitte:
Post-exposure prevention:
I en sammenlagt analyse af to andre studier hos ikke vaccinerede, i øvrigt raske voksne nedsatte 6 ugers behandling med oseltamivir, 75 mg en gang daglig, under en influenzaepidemi signifikant hyppigheden af klinisk influenza hos ikke - vaccinerede, i øvrigt raske voksne, fra 25/ 519 (4, 8%) i placebogruppen til 6/ 520 (1, 2%) i oseltamivirgruppen (76% reduktion [konfidensinterval 1, 6 - 5, 7, p = 0, 0006]).
In a pooled analysis of two other studies conducted in unvaccinated otherwise healthy adults, oseltamivir 75 mg once daily given for 6 weeks significantly reduced the incidence of clinical influenza illness from 25/ 519 (4.8%) in the placebo group to 6/ 520 (1.2%) in the oseltamivir group (76% reduction [95% CI 1.6 – 5.7; p = 0.0006]) during a community outbreak of influenza.
I et studie hos ældre beboere i plejehjem, hvoraf 80% blev vaccineret i studieperioden, nedsatte 6 ugers behandling med oseltamivir, 75 mg en gang daglig, signifikant hyppigheden af klinisk influenza fra 12/ 272 (4, 4%) i placebogruppen til 1/ 276 (0, 4%) i oseltamivirgruppen (92% reduktion [95% konfidensinterval 1, 5 - 6, 6, p=0, 0015]).
A study in elderly residents of nursing homes, where 80% of participants received vaccine in the season of the study, oseltamivir 75 mg once daily given for 6 weeks significantly reduced the incidence of clinical influenza illness from 12/ 272 (4.4%) in the placebo group to 1/ 276 (0.4%) in the oseltamivir group (92% reduction [95% CI 1.5 – 6.6; p = 0.0015]).
Børn Oseltamivirs farmakokinetik er undersøgt i et enkeltdosis farmakokinetisk studie med børn i alderen 1 til 16 år.
Children The pharmacokinetics of oseltamivir have been evaluated in single-dose pharmacokinetic studies in children aged 1 to 16 years.
5. 3 Prækliniske sikkerhedsdata
38 5.3 Preclinical safety data
Gelatine Gul jernoxid (E172) Rød jernoxid (E172) Sort jernoxid (E172) Titandioxid (E171)
Gelatin Yellow iron oxide (E172) Red iron oxide (E172) Black iron oxide (E172) Titanium dioxide (E171)
Det påtrykte blæk:
Printing ink:
Tamiflu 12 mg/ ml pulver til oral suspension.
Tamiflu 12 mg/ ml powder for oral suspension.
1 g pulver til oral suspension indeholder oseltamivirphosphat svarende til 30 mg oseltamivir.
1 g of powder for oral suspension contains oseltamivir phosphate equivalent to 30 mg of oseltamivir.
Efter rekonstituering indeholder hver ml af suspensionen 12 mg oseltamivir.
After reconstitution, each ml of suspension contains 12 mg oseltamivir.
En flaske med rekonstitueret suspension (75 ml), indeholder 900 mg af den aktive substans (oseltamivir).
One bottle of reconstituted suspension (75 ml) contains 900 mg of active substance (oseltamivir).
En flaske med 30 g Tamiflu- pulver til oral suspension indeholder 25, 713g sorbitol.
A bottle of 30 g Tamiflu powder for oral suspension contains 25.713 g of sorbitol.
Den daglige dosis oseltamivir gives som 45 mg to gange dagligt, hvilket bibringer 2, 6 g sorbitol.
One dose of 45 mg oseltamivir administered twice daily delivers 2.6 g of sorbitol.
Pulver til oral suspension Pulveret er et granulat eller klumpet granulat med en hvid til lysegul farve.
Powder for oral suspension The powder is a granulate or clumped granulate with a white to light yellow colour.
- Hos personer, som er 1 år eller ældre, og som har været udsat for smitte af en person med
- Post-exposure prevention in individuals one year of age or older following contact with a
klinisk diagnosticeret influenza, hvis der er influenza i området.
clinically diagnosed influenza case when influenza virus is circulating in the community.
41 4. 2 Dosering og indgivelsesmåde
4.2 Posology and method of administration
Tamiflu- suspensionog Tamiflu kapsler er bioækvivalente formuleringer, og en 75 mg dosis kan gives enten som
75 mg doses can be administered as either
Voksne, unge eller børn (> 40, 0 kg), som kan sluge kapsler, kan tage en tilsvarende dosis som Tamiflu- kapsler.
41 Adults, adolescents or children (> 40 kg) who are able to swallow capsules may receive appropriate doses of Tamiflu capsules.
Den anbefalede orale dosis 75 mg oseltamivir to gange daglig i 5 dage.
The recommended oral dose is 75 mg oseltamivir twice daily for 5 days.
Den anbefalede dosis af Tamiflu oral suspension er anvist i tabellen nedenfor.
The recommended dose of Tamiflu oral suspension is indicated in the table below.
Tamiflu 30 mg og 45 mg kapsler er tilgængelige som et alternativ til den anbefalede dosis af Tamiflu- suspensionen.
Tamiflu 30 mg and 45 mg capsules are available as an alternative to the recommended dose of Tamiflu suspension.
Afhængig af legemsvægt anbefales følgende doser:
The following weight-adjusted dosing regimens are recommended:
Legemsvægt i kg ≤ 15 kg > 15 kg til 23 kg > 23 kg til 40 kg > 40 kg
≤ 15 kg > 15 kg to 23 kg > 23 kg to 40 kg > 40 kg
Anbefalet dosis i 5 dage 30 mg to gange daglig 45 mg to gange daglig 60 mg to gange daglig 75 mg to gange daglig
30 mg twice daily 45 mg twice daily 60 mg twice daily 75 mg twice daily
30 mg, 45 mg og 60 mg.
For dosing, an oral dispenser with 30 mg, 45 mg and 60 mg graduations is provided in the box.
Til nøjagtig dosering må der kun anvendes den vedlagte orale dispenser.
For accurate dosing, the oral dispenser supplied should be used exclusively.